The Italian Group, who employs 3,600 people throughout the world, has established itself as a world leader in the field of cardiovascular disease, particularly in heart surgery, through cardiopulmonary assistance, heart rhythm disorder treatment (representing 38% of the business) and heart valves. This new centre of excellence designs and manufactures the world's smallest implanted defibrillators and pacemakers used in regulating heart rhythm, as well as cardiac resynchronisation devices used in treating cardiac insufficiency and arrhythmia recording and analysing systems. From now on, it will gather all of the Group's research and production power in this field upon a single site, over a total surface area of 12,000 sq. m., thus making up a Group world showcase in the diagnosis and treatment of heart rhythm disorders.

It was not by chance that the Group chose to locate the centre in the Paris Region. For over 40 years, Sorin has been maintaining a close relationship with major hospitals, public research institutions like the INRIA, the INSERM and the CNRS, and industrial players including the CEA, the LETI, STMICROELECTRONICS and Orange-France Telecom (for a telecardiology project).  Not to mention young companies like 3D+, Neurelec and others. Ideally located south-west of Paris, the centre will represent a strategic foothold for the Group's worldwide growth. Indeed, 75% of production coming out of Clamart is exported throughout the world. In addition, the Paris Region possesses a host of clusters of excellence in the medical field as well as highly qualified human resources. Out of the 500 employees working at the Clamart centre, 32% are highly qualified R&D technicians and engineers. It should be mentioned that 18% of the turnover is devoted to R&D, and the Sorin Group has in fact invested over €200m in R&D in France over the past decade. The Group plans on increasing its workforce by 10% yearly on average in highly qualified and long-lasting jobs.